Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01232569




Registration number
NCT01232569
Ethics application status
Date submitted
1/11/2010
Date registered
2/11/2010
Date last updated
29/07/2015

Titles & IDs
Public title
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Scientific title
A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Secondary ID [1] 0 0
2010-019912-18
Secondary ID [2] 0 0
NA25220
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tocilizumab 162 mg
Treatment: Drugs - Placebo

Experimental: Tocilizumab 162 mg sc - Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.

Placebo comparator: Placebo sc - Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.


Treatment: Drugs: Tocilizumab 162 mg
Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.

Treatment: Drugs: Placebo
Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24
Timepoint [1] 0 0
Baseline to Week 24
Secondary outcome [1] 0 0
Percentage of Patients With ACR50 and ACR70 Responses at Week 24
Timepoint [1] 0 0
Baseline to Week 24
Secondary outcome [2] 0 0
Time to Onset of ACR20, ACR50, and ACR70 Responses
Timepoint [2] 0 0
Baseline to Week 24
Secondary outcome [3] 0 0
Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 24
Timepoint [3] 0 0
Baseline to Week 24
Secondary outcome [4] 0 0
Change From Baseline in C-reactive Protein at Week 24
Timepoint [4] 0 0
Baseline to Week 24
Secondary outcome [5] 0 0
Change From Baseline in Erythrocyte Sedimentation Rate at Week 24
Timepoint [5] 0 0
Baseline to Week 24
Secondary outcome [6] 0 0
Change From Baseline in the Patient's and the Physician's Global Assessment of Disease Activity Visual Analog (VAS) Score
Timepoint [6] 0 0
Baseline to Week 24
Secondary outcome [7] 0 0
Change From Baseline in the Patient's Pain Visual Analog Score
Timepoint [7] 0 0
Baseline to Week 24
Secondary outcome [8] 0 0
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
Timepoint [8] 0 0
Baseline to Week 24
Secondary outcome [9] 0 0
Percentage of Patients With an Improvement of = 0.3 Units From Baseline in the HAQ-DI Score at Week 24
Timepoint [9] 0 0
Baseline to Week 24
Secondary outcome [10] 0 0
Change From Baseline in Disease Activity Score 28 (DAS28) at Week 24
Timepoint [10] 0 0
Baseline to Week 24
Secondary outcome [11] 0 0
Percentage of Patients With a DAS28 Score = 3.2 (DAS28 Low Disease Activity) at Week 24
Timepoint [11] 0 0
Baseline to Week 24
Secondary outcome [12] 0 0
Percentage of Patients With a DAS28 Score < 2.6 (DAS28 Remission) at Week 24
Timepoint [12] 0 0
Week 24
Secondary outcome [13] 0 0
Percentage of Patients With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses at Week 24
Timepoint [13] 0 0
Baseline to Week 24
Secondary outcome [14] 0 0
Change From Baseline in the Van Der Heijde Modified Sharp Radiographic Score at Week 24
Timepoint [14] 0 0
Baseline to Week 24
Secondary outcome [15] 0 0
Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey at Week 24
Timepoint [15] 0 0
Baseline to Week 24
Secondary outcome [16] 0 0
Change From Baseline in Hemoglobin at Week 24
Timepoint [16] 0 0
Baseline to Week 24

Eligibility
Key inclusion criteria
* Adult patients, = years of age.
* Moderate to severe rheumatoid arthritis of = 6 months duration.
* Receiving treatment on an outpatient basis.
* Swollen joint count (SJC) = 6 (66 joint count) and tender joint count (TJC)= 8 (68 joint count) at screening and study start.
* On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
* Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.
* Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.
* Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.
* Prior history of or current inflammatory joint disease other than rheumatoid arthritis.
* History of malignancy, active or recurrent infections, positive to hepatitis B surface antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or a history of diverticular disease or other symptomatic GI conditions that might predispose to perforations.

Other inclusion and exclusion criteria applied to the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2013
Sample size
Target
Accrual to date
Final
656
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Cairns
Recruitment hospital [2] 0 0
- Kogarah
Recruitment postcode(s) [1] 0 0
4870 - Cairns
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Mississippi
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nebraska
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Oklahoma
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Córdoba
Country [21] 0 0
Argentina
State/province [21] 0 0
San Miguel de Tucuman
Country [22] 0 0
Brazil
State/province [22] 0 0
Curitiba
Country [23] 0 0
Brazil
State/province [23] 0 0
Goiania
Country [24] 0 0
Brazil
State/province [24] 0 0
Juiz de Fora
Country [25] 0 0
Brazil
State/province [25] 0 0
Porto Alegre
Country [26] 0 0
Brazil
State/province [26] 0 0
Rio de Janeiro
Country [27] 0 0
Brazil
State/province [27] 0 0
Salvador
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Paulo
Country [29] 0 0
Brazil
State/province [29] 0 0
São Paulo
Country [30] 0 0
Brazil
State/province [30] 0 0
Vitoria
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Plovdiv
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Sofia
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Varna
Country [34] 0 0
Canada
State/province [34] 0 0
Alberta
Country [35] 0 0
Canada
State/province [35] 0 0
Manitoba
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Colombia
State/province [38] 0 0
Bogota
Country [39] 0 0
Colombia
State/province [39] 0 0
Chia-cundinamarca
Country [40] 0 0
Colombia
State/province [40] 0 0
Medellin
Country [41] 0 0
Greece
State/province [41] 0 0
Athens
Country [42] 0 0
Greece
State/province [42] 0 0
Thessaloniki
Country [43] 0 0
Guatemala
State/province [43] 0 0
Guatemala City
Country [44] 0 0
Hungary
State/province [44] 0 0
Budapest
Country [45] 0 0
Hungary
State/province [45] 0 0
Debrecen
Country [46] 0 0
Israel
State/province [46] 0 0
Ashkelon
Country [47] 0 0
Israel
State/province [47] 0 0
Beer Sheva
Country [48] 0 0
Israel
State/province [48] 0 0
Haifa
Country [49] 0 0
Israel
State/province [49] 0 0
Ramat Gan
Country [50] 0 0
Israel
State/province [50] 0 0
Rishon Lezion
Country [51] 0 0
Israel
State/province [51] 0 0
Tel Aviv
Country [52] 0 0
Malaysia
State/province [52] 0 0
Batu Caves
Country [53] 0 0
Malaysia
State/province [53] 0 0
Kota Kinabalu
Country [54] 0 0
Malaysia
State/province [54] 0 0
Kuala Lumpur
Country [55] 0 0
Mexico
State/province [55] 0 0
Chihuahua
Country [56] 0 0
Mexico
State/province [56] 0 0
Culiacan
Country [57] 0 0
Mexico
State/province [57] 0 0
Guadalajara
Country [58] 0 0
Mexico
State/province [58] 0 0
Leon
Country [59] 0 0
Mexico
State/province [59] 0 0
Merida
Country [60] 0 0
Mexico
State/province [60] 0 0
Mexicali
Country [61] 0 0
Mexico
State/province [61] 0 0
Mexico
Country [62] 0 0
Mexico
State/province [62] 0 0
Morelia
Country [63] 0 0
Mexico
State/province [63] 0 0
Obregon
Country [64] 0 0
Mexico
State/province [64] 0 0
Queretaro
Country [65] 0 0
New Zealand
State/province [65] 0 0
Otahuhu
Country [66] 0 0
Panama
State/province [66] 0 0
Panama City
Country [67] 0 0
Philippines
State/province [67] 0 0
Cebu
Country [68] 0 0
Philippines
State/province [68] 0 0
Davao
Country [69] 0 0
Philippines
State/province [69] 0 0
Manila
Country [70] 0 0
Poland
State/province [70] 0 0
Bytom
Country [71] 0 0
Poland
State/province [71] 0 0
Dzialdowo
Country [72] 0 0
Poland
State/province [72] 0 0
Elblag
Country [73] 0 0
Poland
State/province [73] 0 0
Koscian
Country [74] 0 0
Poland
State/province [74] 0 0
Krakow
Country [75] 0 0
Poland
State/province [75] 0 0
Torun
Country [76] 0 0
Poland
State/province [76] 0 0
Warszawa
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Kemerovo
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Moscow
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Novosibirsk
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Petrozavodsk
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Ryazan
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Saint-petersburg
Country [83] 0 0
Russian Federation
State/province [83] 0 0
St Petersburg
Country [84] 0 0
Russian Federation
State/province [84] 0 0
UFA
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Voronezh
Country [86] 0 0
South Africa
State/province [86] 0 0
Durban
Country [87] 0 0
South Africa
State/province [87] 0 0
Pinelands
Country [88] 0 0
South Africa
State/province [88] 0 0
Pretoria
Country [89] 0 0
Spain
State/province [89] 0 0
La Coruna
Country [90] 0 0
Spain
State/province [90] 0 0
Oviedo
Country [91] 0 0
Spain
State/province [91] 0 0
Sevilla
Country [92] 0 0
Switzerland
State/province [92] 0 0
Fribourg
Country [93] 0 0
Switzerland
State/province [93] 0 0
Genève
Country [94] 0 0
Switzerland
State/province [94] 0 0
Lausanne
Country [95] 0 0
Switzerland
State/province [95] 0 0
Zürich
Country [96] 0 0
Thailand
State/province [96] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.
Trial website
https://clinicaltrials.gov/study/NCT01232569
Trial related presentations / publications
Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61. doi: 10.1002/acr.22384.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01232569